CXCL12/CXCR4 blockade induces multimodal antitumor effects that prolong survival in an immunocompetent mouse model of ovarian cancer

Cancer Research

Volumn 71, Issue 16, 2011, Pages 5522-5534

  Righi, Elda ^a,c   Kashiwagi, Satoshi ^a   Yuan, Jianping ^a   Santosuosso, Michael ^a   Leblanc, Pierre ^a   Ingraham, Rachel ^a   Forbes, Benjamin ^a   Edelblute, Beth ^a   Collette, Brian ^a   Xing, Deyin ^a   Kowalski, Magdalena ^a,e   Mingari, Maria Cristina ^c   Vianello, Fabrizio ^d   Birrer, Michael ^a   Orsulic, Sandra ^a,f   Dranoff, Glenn ^b   Poznansky, Mark C ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c UNIVERSITY OF GENOA   (Italy)

^d UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^e CLARE COLLEGE   (United Kingdom)

^f CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; PLERIXAFOR; SMALL INTERFERING RNA; STROMAL CELL DERIVED FACTOR 1; TRANSCRIPTION FACTOR FOXP3;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; IMMUNE RESPONSE; IMMUNOCOMPETENCE; IN VITRO STUDY; IN VIVO STUDY; METASTASIS; MOUSE; NECROSIS; NONHUMAN; OVARY CANCER; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECEPTOR BLOCKING; REGULATORY T LYMPHOCYTE; RISK REDUCTION; SURVIVAL TIME; TUMOR GROWTH; TUMOR IMMUNITY;

ANIMALS; APOPTOSIS; CELL PROLIFERATION; CHEMOKINE CXCL12; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE KNOCKDOWN TECHNIQUES; IMMUNOCOMPETENCE; MICE; OVARIAN NEOPLASMS; RECEPTORS, CXCR4; RNA INTERFERENCE; SURVIVAL RATE;

EID: 80051690814     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-3143     Document Type: Article

References (53)

1. Kulbe H, Thompson R, Wilson JL, Robinson S, Hagemann T, Fatah R, et al. The inflammatory cytokine tumor necrosis factor-alpha generates an autocrine tumor-promoting network in epithelial ovarian cancer cells. Cancer Res 2007;67:585-92. (Pubitemid 46192196)
2. Milliken D, Scotton C, Raju S, Balkwill F, Wilson J. Analysis of chemokines and chemokine receptor expression in ovarian cancer ascites. Clin Cancer Res 2002;8:1108-14. (Pubitemid 35177363)
3. Negus RP, Stamp GW, Hadley J, Balkwill FR. Quantitative assessment of the leukocyte infiltrate in ovarian cancer and its relationship to the expression of C-C chemokines. Am J Pathol 1997;150:1723-34. (Pubitemid 27193819)
4. Ochsenbein AF. Principles of tumor immunosurveillance and implications for immunotherapy. Cancer Gene Ther 2002;9:1043-55. (Pubitemid 35462566)
5. Schimanski CC, Galle PR, Moehler M. Chemokine receptor CXCR4-prognostic factor for gastrointestinal tumors. World J Gastroenterol 2008;14:4721-4.
6. Webb TJ, Giuntoli RL 2nd, Rogers O, Schneck J, Oelke M. Ascites specific inhibition of CD1d-mediated activation of natural killer T-cells. Clin Cancer Res 2008;14:7652-8.
7. Balkwill F. The significance of cancer cell expression of the chemokine receptor CXCR4. Semin Cancer Biol 2004;14:171-9. (Pubitemid 38586742)
8. Muller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001;410:50-6. (Pubitemid 32225831)
9. + cell infiltration with human papillomavirus infection and clinicopathological progression of cervical cancer. Am J Pathol 2009;175:1525-35.
10. Lee CH, Kakinuma T, Wang J, Zhang H, Palmer DC, Restifo NP, et al. Sensitization of B16 tumor cells with a CXCR4 antagonist increases the efficacy of immunotherapy for established lung metastases. Mol Cancer Ther 2006;5:2592-9. (Pubitemid 44650924)
11. Marchesi F, Monti P, Leone BE, Zerbi A, Vecchi A, Piemonti L, et al. Increased survival, proliferation, and migration in metastatic human pancreatic tumor cells expressing functional CXCR4. Cancer Res 2004;64:8420-7. (Pubitemid 39491782)
12. Smith MC, Luker KE, Garbow JR, Prior JL, Jackson E, Piwnica-Worms D, et al. CXCR4 regulates growth of both primary and metastatic breast cancer. Cancer Res 2004;64:8604-12. (Pubitemid 39552073)
13. Zhou Y, Larsen PH, Hao C, Yong VW. CXCR4 is a major chemokine receptor on glioma cells and mediates their survival. J Biol Chem 2002;277:49481-7. (Pubitemid 36014384)
14. Scotton C, Milliken D, Wilson J, Raju S, Balkwill F. Analysis of CC chemokine and chemokine receptor expression in solid ovarian tumours. Br J Cancer 2001;85:891-7. (Pubitemid 33010558)
15. Scotton CJ, Wilson JL, Milliken D, Stamp G, Balkwill FR. Epithelial cancer cell migration: a role for chemokine receptors? Cancer Res 2001;61:4961-5. (Pubitemid 32681518)
16. Scotton CJ, Wilson JL, Scott K, Stamp G, Wilbanks GD, Fricker S, et al. Multiple actions of the chemokine CXCL12 on epithelial tumor cells in human ovarian cancer. Cancer Res 2002;62:5930-8. (Pubitemid 35204756)
17. Helbig G, Christopherson KW 2nd, Bhat-Nakshatri P, Kumar S, Kishimoto H, Miller KD, et al. NF-kappaB promotes breast cancer cell migration and metastasis by inducing the expression of the chemokine receptor CXCR4. J Biol Chem 2003;278:21631-8. (Pubitemid 36792563)
18. Kukreja P, Abdel-Mageed AB, Mondal D, Liu K, Agrawal KC. Upregulation of CXCR4 expression in PC-3 cells by stromal-derived factor-1alpha (CXCL12) increases endothelial adhesion and transendothelial migration: role of MEK/ERK signaling pathway-dependent NF-kappaB activation. Cancer Res 2005;65:9891-8. (Pubitemid 41541469)
19. Kryczek I, Lange A, Mottram P, Alvarez X, Cheng P, Hogan M, et al. CXCL12 and vascular endothelial growth factor synergistically induce neoangiogenesis in human ovarian cancers. Cancer Res 2005;65:465-72.
20. Kryczek I, Wei S, Keller E, Liu R, Zou W. Stroma-derived factor (SDF-1/CXCL12) and human tumor pathogenesis. Am J Physiol Cell Physiol 2007;292:C987-95. (Pubitemid 46440396)
21. Kajiyama H, Shibata K, Terauchi M, Ino K, Nawa A, Kikkawa F. Involvement of SDF-1alpha/CXCR4 axis in the enhanced peritoneal metastasis of epithelial ovarian carcinoma. Int J Cancer 2008;122:91-9. (Pubitemid 350209982)
22. Dunussi-Joannopoulos K, Zuberek K, Runyon K, Hawley RG,Wong A, Erickson J, et al. Efficacious immunomodulatory activity of the chemokine stromal cell-derived factor 1 (SDF-1): local secretion of SDF-1 at the tumor site serves as T-cell chemoattractant and mediates T-cell-dependent antitumor responses. Blood 2002;100:1551-8. (Pubitemid 34925126)
23. Youn JI, Nagaraj S, Collazo M, Gabrilovich DI. Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J Immunol 2008;181:5791-802.
24. Zou W, Machelon V, Coulomb-L'Hermin A, Borvak J, Nome F, Isaeva T, et al. Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells. Nat Med 2001;7:1339-46. (Pubitemid 34007939)
25. Vianello F, Papeta N, Chen T, Kraft P, White N, Hart WK, et al. Murine B16 melanomas expressing high levels of the chemokine stromal-derived factor-1/CXCL12 induce tumor-specific T-cell chemorepulsion and escape from immune control. J Immunol 2006;176:2902-14.
26. + cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin's lymphoma. J Clin Oncol 2004;22:1095-102.
27. Liles WC, Broxmeyer HE, Rodger E, Wood B, Hubel K, Cooper S, et al. Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist. Blood 2003;102:2728-30. (Pubitemid 37248839)
28. Xing D, Orsulic S. A mouse model for the molecular characterization of brca1-associated ovarian carcinoma. Cancer Res 2006;66:8949-53. (Pubitemid 44521109)
29. Fidler IJ. Selection of successive tumour lines for metastasis. Nat New Biol 1973;242:148-9.
30. Kashiwagi S, Izumi Y, Gohongi T, Demou ZN, Xu L, Huang PL, et al. NO mediates mural cell recruitment and vessel morphogenesis in murine melanomas and tissue-engineered blood vessels. J Clin Invest 2005;115:1816-27. (Pubitemid 40979720)
31. Santosuosso M, McCormick S, Roediger E, Zhang X, Zganiacz A, Lichty BD, et al. Mucosal luminal manipulation of T-cell geography switches on protective efficacy by otherwise ineffective parenteral genetic immunization. J Immunol 2007;178:2387-95. (Pubitemid 46233438)
32. + T-cell epitopes in a FVB/N rat HER-2/neu mouse model of breast cancer. Cancer Res 2006;66:7748-57.
33. Poznansky MC, Olszak IT, Foxall R, Evans RH, Luster AD, Scadden DT. Active movement of T-cells away from a chemokine. Nat Med 2000;6:543-8. (Pubitemid 30305904)
34. Bast RC Jr, Hennessy B, Mills GB. The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer 2009;9:415-28.
35. Datema R, Rabin L, Hincenbergs M, Moreno MB, Warren S, Linquist V, et al. Antiviral efficacy in vivo of the anti-human immunodeficiency virus bicyclam SDZ SID 791 (JM 3100), an inhibitor of infectious cell entry. Antimicrob Agents Chemother 1996;40:750-4. (Pubitemid 26075438)
36. Mirshahi F, Pourtau J, Li H, Muraine M, Trochon V, Legrand E, et al. SDF-1 activity on microvascular endothelial cells: consequences on angiogenesis in in vitro and in vivo models. Thromb Res 2000;99:587-94. (Pubitemid 30642740)
37. Hartmann TN, Burger JA, Glodek A, Fujii N, Burger M. CXCR4 chemokine receptor and integrin signaling co-operate in mediating adhesion and chemoresistance in small cell lung cancer (SCLC) cells. Oncogene 2005;24:4462-71. (Pubitemid 40961769)
38. Muller A, Sonkoly E, Eulert C, Gerber PA, Kubitza R, Schirlau K, et al. Chemokine receptors in head and neck cancer: association with metastatic spread and regulation during chemotherapy. Int J Cancer 2006;118:2147-57.
39. + regulatory T-cells that traffic through CXCL12/CXCR4 signals. Cancer Res 2004;64:8451-5.
40. +/regulatory T-cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A 2005;102:18538-43.
41. van der Meulen AA, Biber K, Lukovac S, Balasubramaniyan V, den Dunnen WF, Boddeke HW, et al. The role of CXC chemokine ligand (CXCL)12-CXC chemokine receptor (CXCR)4 signalling in the migration of neural stem cells towards a brain tumour. Neuropathol Appl Neurobiol 2009;35:579-91.
42. Sun X, Cheng G, Hao M, Zheng J, Zhou X, Zhang J, et al. CXCL12/CXCR4/CXCR7 chemokine axis and cancer progression. Cancer Metastasis Rev 2010;29:709-22.
43. Sehgal A, Keener C, Boynton AL, Warrick J, Murphy GP. CXCR-4, a chemokine receptor, is overexpressed in and required for proliferation of glioblastoma tumor cells. J Surg Oncol 1998;69:99-104. (Pubitemid 28515968)
44. Barbero S, Bonavia R, Bajetto A, Porcile C, Pirani P, Ravetti JL, et al. Stromal cell-derived factor 1alpha stimulates human glioblastoma cell growth through the activation of both extracellular signal-regulated kinases 1/2 and Akt. Cancer Res 2003;63:1969-74. (Pubitemid 36460865)
45. Redjal N, Chan JA, Segal RA, Kung AL. CXCR4 inhibition synergizes with cytotoxic chemotherapy in gliomas. Clin Cancer Res 2006;12:6765-71. (Pubitemid 44876846)
46. Curiel TJ, Cheng P, Mottram P, Alvarez X, Moons L, Evdemon-Hogan M, et al. Dendritic cell subsets differentially regulate angiogenesis in human ovarian cancer. Cancer Res 2004;64:5535-8. (Pubitemid 39095544)
47. Li B, Lalani AS, Harding TC, Luan B, Koprivnikar K, Huan Tu G, et al. Vascular endothelial growth factor blockade reduces intratumoral regulatory T-cells and enhances the efficacy of a GM-CSF-secreting cancer immunotherapy. Clin Cancer Res 2006;12:6808-16. (Pubitemid 44876851)
48. Manning EA, Ullman JG, Leatherman JM, Asquith JM, Hansen TR, Armstrong TD, et al. A vascular endothelial growth factor receptor-2 inhibitor enhances antitumor immunity through an immune-based mechanism. Clin Cancer Res 2007;13:3951-9. (Pubitemid 47037603)
49. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, et al. Specific recruitment of regulatory T-cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004;10:942-9. (Pubitemid 39273735)
50. Chen YL, Fang JH, Lai MD, Shan YS. Depletion of CD4(+)CD25(+) regulatory T-cells can promote local immunity to suppress tumor growth in benzo[α]pyrene-induced forestomach carcinoma. World J Gastroenterol 2008;14:5797-809.
51. Yoshimura K, Laird LS, Chia CY,Meckel KF, Slansky JE, Thompson JM, et al. Live attenuated Listeria monocytogenes effectively treats hepatic colorectal cancer metastases and is strongly enhanced by depletion of regulatory T-cells. Cancer Res 2007;67:10058-66. (Pubitemid 47621257)
52. Tuve S, Chen BM, Liu Y, Cheng TL, Toure P, Sow PS, et al. Combination of tumor site-located CTL-associated antigen-4 blockade and systemic regulatory T-cell depletion induces tumor-destructive immune responses. Cancer Res 2007;67:5929-39. (Pubitemid 46985029)
53. Colombo MP, Piconese S. Regulatory-T-cell inhibition versus depletion: the right choice in cancer immunotherapy. Nat Rev Cancer 2007;7:880-7. (Pubitemid 350006256)